VSIG4 and neoplasm: However, in all animals, tumor growth largely depends on the TME immune composition of that individual animal regardless of the treatment, and anti-VSIG4 and anti-PD-1 treatments tend to shift the TME immune composition toward increased immune surveillance and decreased tumor growth.